# Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)

> **NCT03064490** · PHASE2 · COMPLETED · sponsor: **Duke University** · enrollment: 35 (actual)

## Conditions studied

- Locally Advanced Esophageal and Gastric Cancers (EGC)

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03064490
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2023-02-24
- **Final completion:** 2023-11-22
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03064490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03064490, "Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03064490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*